|
|
Volumn 7, Issue 9, 2017, Pages OF2-
|
|
Epacadostat Shows Value in Two SCCHN Trials
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPACADOSTAT;
INDOLEAMINE 2,3 DIOXYGENASE;
INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN;
MONOCLONAL ANTIBODY;
NIVOLUMAB;
OXIME;
PDCD1 PROTEIN, MOUSE;
PEMBROLIZUMAB;
PROGRAMMED DEATH 1 RECEPTOR;
SULFONAMIDE;
ANTAGONISTS AND INHIBITORS;
CLINICAL TRIAL (TOPIC);
GENETICS;
HEAD AND NECK TUMOR;
HUMAN;
IMMUNOLOGY;
PATHOLOGY;
SQUAMOUS CELL CARCINOMA;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, SQUAMOUS CELL;
CLINICAL TRIALS AS TOPIC;
HEAD AND NECK NEOPLASMS;
HUMANS;
INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE;
OXIMES;
PROGRAMMED CELL DEATH 1 RECEPTOR;
SULFONAMIDES;
|
|
EID: 85045727921
PISSN: None
EISSN: 21598290
Source Type: Journal
DOI: 10.1158/2159-8290.CD-NB2017-100 Document Type: Article |
|
Times cited : (24)
|
|
References (0)
|